novo nordisk chronic kidney disease

Novo Nordisk’s Ozempic Gets FDA Approval

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

Bloomberg on MSN · 1d

Novo’s Ozempic Gains US Nod for Kidney Disease, Widening Use

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

2don MSN

Novo Nordisk's Ozempic gets FDA approval for kidney disease

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...

BioPharma Dive4h

Metsera, Maze secure combined $415 million in IPOs

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

14h

Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Renal & Urology News15h

KDIGO Issues New ADPKD Guideline

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results